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SUPPLEMENTARY METHODS 
1.  Chemistry 
General Experimental 
Melting points were obtained on OptiMelt Automated Melting Point System with Digital Image Processing 
Technology and are uncorrected. 1H NMR and 13C NMR were recorded at the Nuclear Magnetic Resonance 
Facility within the Mark Wainwright Analytical Centre at The University of New South Wales on a Bruker 
Avance III 300 (300 MHz), Bruker DPX 300 (300 MHz), Bruker Avance III 400 (400 MHz), Bruker Avance III 
500 (500 MHz) or Bruker Avance III 600 (600 MHz), with data acquired and processed using TopSpin 3.0 
software. Chemical shifts are expressed in parts per million (ppm) on the δ scale. Chemical shifts in CDCl3 
were referenced relative to CHCl3 (7.26 ppm) for 1H NMR and CHCl3 (77.16 ppm) for 13C NMR.1 Infrared 
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spectra were obtained on a ThermoNicolet Avatar 370 FT–IR spectrometer and are reported in wavenumbers 
(cm–1). Spectra were recorded from thin films using NaCl plates. HRMS were performed at the Bioanalytical 
Mass Spectrometry Facility within the Mark Wainwright Analytical Centre at The University of New South 
Wales on an Orbitrap LTQ XL (Thermo Fisher Scientific, San Jose, Ca, USA) ion trap mass spectrometer 
using a nanospray (nano-electrospray) ionization source to generate ions from the analyte in solution. The 
instrument was calibrated with a standard calibration solution (as outlined in the instrument manual) on the day 
of analysis using direct infusion with the nanospray source. The instrument conditions were optimized for 
sensitivity on each compound of interest using LC tune software. The analysis was carried out in positive ion 
mode using the orbitrap FTMS analyser at a resolution of 100000. Samples, 5 µL, (1 µg/mL in methanol or 
acetonitrile), were injected into a glass needle and inserted into the nanospray source. Ions generated were 
measured over the mass range 150 to 2000. Data was acquired in full scan mode over 60 seconds. Data was 
analyzed using the Qual Browser feature in Xcaliber 2.1 (Thermo Fisher Scientific, San Jose, Ca, USA). LCMS 
was routinely performed using a Shimadzu Prominence High Performance LCMS 2010EV (Phenomenex C18 
column, 5 µm, 150 × 2 mm) connected to an autosampler, photo diode array (PDA) lamp detection (190-600 
nm) and Shimadzu LCMS 2010EV mass spectrometer. The mobile phase consisted of MilliQ water with 0.1 % 
(v/v) TFA (Solvent A) and HPLC grade acetonitrile with 0.1 % (v/v) TFA (Solvent B) at a flow rate of 0.2 
mL/min using the gradient in the following table. 
Time (min) Solvent A (%) Solvent B (%) 
0 95 5 
2 95 5 
20 0 100 
22 0 100 
22 95 5 
30 95 5 
Unless otherwise stated all reactions were performed in flame dried glassware under an atmosphere of dry 
argon. Reaction temperatures refer to the external bath temperature. Concentration of solvents was performed 
under reduced pressure on a rotary evaporator after which, residual solvent was removed under high vacuum 
(~0.1 mm/Hg). 
Reagents and solvents were purchased from commercial sources and used without further purification, unless 
stated below. Reagents and solvents used in reactions were purified according to well established 
procedures.1,2 In particular, tetrahydrofuran (THF) was freshly distilled from sodium and benzophenone under 
an inert atmosphere of argon. N,N-Dimethylformamide (DMF) was dried sequentially over three batches of 4Ǻ 
molecular sieves (3 × 24 h), before finally being stored over a fourth batch of 4Ǻ molecular sieves, under argon. 
To remove residual N,N-dimethylamine from DMF, the solvent was evacuated (~0.1 mm/Hg) for at least 30 
min prior to use. Methanol was distilled from magnesium and stored over 3Ǻ molecular sieves, under argon. 
Dichloromethane was distilled from calcium hydride and stored over 4Ǻ molecular sieves. Petroleum spirit 
used for chromatography was of the fraction 40-60°C.  
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Analytical thin layer chromatography was conducted on Merck, aluminium-backed silica plates 60 F254 or silica 
gel 60 RP-C18 F254 plates and visualised using UV light and stained with a dip of either a potassium 
permanganate, vanillin or phosphomolybdic acid. Flash chromatography was routinely performed using Grace 
Davison Discovery Sciences, Davisil LC60A 40 – 63 micron silica gel, following published guidelines.3 Solvent 
was eluted using a Thomson SINGLE StEP pump at the flow rate recommended by the manufacturer 
(Thomson Instrument Company, Oceanside, Ca, USA). Deactivated silica gel was prepared by washing a 
column packed with silica gel with neat triethylamine (5 column volumes). After drying, the column was 
washed with petroleum spirit to remove any residual triethylamine. 
 
Synthesis and Characterisation 
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S4 R = Me
S5 R = CH2CH2NMe2
S6 R = CH2-2-pyridine
R = Me quant. (over 2 steps)
R = CH2CH2NMe2 93% (over 2 steps)
R = CH2-2-pyridine 70% (over 2 steps)
2.5 eq. NaHCO3, THF (1 M),
R = Me 71 %
R = CH2CH2NMe2 84%
R = CH2-2-pyridine 67%
 
 
General Procedures for the Synthesis of S4, S5 and S6 
(1)  A solution of piperazine (1 equiv.), benzotrifluoride (1 equiv.) and sodium bicarbonate (2.5 equiv.) in 
THF (1 M) was heated at reflux for 16 hours. The solution was allowed to cool to room temperature and the 
reaction solution was filtered through a short pad of Celite, eluting with ethyl acetate. The solvent was 
removed under reduced pressure to afford the product, which was of sufficient purity to use in the next step. 
On occasion when the crude product was impure it could be purified by flash chromatography on deactivated 
silica gel to afford the product. 
 
1-Methyl-4-(2-nitro-4-(trifluoromethyl)phenyl)piperazine (S1)4 
1H NMR (300 MHz, CDCl3) δ 2.36 (s, 3H), 2.56-2.59 (m, 4H), 3.16-3.19 (m, 4H), 7.16 (d, J = 
8.7 Hz, 1H), 7.66 (d, J = 8.7 Hz, 1H), 8.04 (s, 1H) 
13C NMR (75 MHz, CDCl3) δ 46.1, 50.9, 54.6, 120.6, 122.7 (q, JC-F = 34.5 Hz), 123.6 (q, JC-F 
= 270.0 Hz), 124.3 (q, JC-F = 3.8 Hz), 130.2 (q, JC-F = 3.8 Hz), 140.7, 148.1 
IR (NaCl, neat): 1536 cm-1 
HRMS (ESI-MS): m/z calcd for C12H15F3N3O2 (M+H)+ 290.1116, found 290.1111. 
 
N,N-Dimethyl-2-(4-(2-nitro-4-(trifluoromethyl)phenyl)piperazin-1-yl)ethan-1-amine (S2) 
1H NMR (300 MHz, CDCl3) δ 2.29 (s, 6H), 2.47 – 2.52 (m, 2H), 2.56 – 2.61 (m, 2H), 2.63 – 
2.66 (m, 4H), 3.17 – 3.20 (m, 4H), 7.15 (d, J = 8.7 Hz, 1H), 7.65 (dd, J = 8.7, 1.8 Hz, 1H), 
8.04 (d, J = 1.8 Hz, 1H) 
13C NMR (75 MHz, CDCl3) δ 46.0, 50.9, 53.2, 56.6, 56.9, 120.6, 122.2 (q, JC-F = 33.8 Hz), 
123.4 (q, JC-F = 270 Hz), 124.3 (q, JC-F = 3.8 Hz), 130.2 (q, JC-F = 3.8 Hz), 140.7, 148.1 
IR (NaCl, neat): 1537 cm-1 
HRMS (ESI-MS): m/z calcd for C15H22F3N4O2 (M++H) 347.1695, found 347.1689 
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1-(2-Nitro-4-(trifluoromethyl)phenyl)-4-(pyridin-2-ylmethyl)piperazine (S3) 
1H NMR (500 MHz, CDCl3) δ 2.67 – 2.69 (m, 4H), 3.20 – 3.22 (m, 4H), 3.73 (s, 2H), 7.15 (d, J 
= 8.8 Hz, 1H), 7.17 – 7.20 (m, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.63 – 7.68 (m, 2H), 8.03 (br s, 
1H), 8.59 (d, J = 4.8 Hz, 1H) 
13C NMR (75 MHz, CDCl3) δ 50.9, 52.9, 64.5, 120.6, 122.1 (q, JC-F = 34.7 Hz), 122.4, 123.4 
(q, JC-F = 270.8 Hz), 123.5, 124.3 (q, JC-F = 3.9 Hz), 130.2 (q, JC-F = 3.5 Hz), 136.6, 140.6, 
148.1, 149.6, 158.0 
IR (NaCl, neat): 1625 cm-1 
HRMS (ESI-MS): m/z calcd for C17H17F3N4O2Na (M++Na) 389.1201, found 389.1185 
 (2) Hydrazine hydrate (25 equiv.) was added dropwise to a suspension of nitrocompound S1, S2 or S3 (1 
equiv.), iron(III) chloride hexahydrate (20 mol %) and activated carbon (20 % wt./wt.) in methanol (0.1 M) at 
room temperature. The solution was heated at reflux for two hours. The solution was allowed to cool to room 
temperature then filtered through a short pad of Celite, eluting with ethyl acetate. The solvent was removed 
under reduced pressure. The residue was diluted with water and extracted with ethyl acetate (× 3). The 
organic extracts were combined and dried (Na2SO4). The solvent was removed under reduced pressure to 
afford the product as a white solid, which was of sufficient purity to use in the next step. 
 
2-(4-Methylpiperazin-1-yl)-5-(trifluoromethyl)aniline (S4)4 
1H NMR (300 MHz, CDCl3) δ 2.42 (s, 3H), 2.52-2.65 (m, 4H), 2.99-3.02 (m, 4H), 4.05 (br s, 
2H), 6.93-7.03 (m, 3H) 
13C NMR (75 MHz, CDCl3) δ 46.3, 50.7, 55.8, 111.6 (q, JC-F = 3.8 Hz), 115.5 (q, JC-F = 3.8 
Hz), 119.7, 124.5 (q, JC-F = 270.1 Hz), 126.1 (q, JC-F = 33.4 Hz), 141.6, 142.1 
IR (NaCl, neat): 3465 cm-1 
HRMS (ESI-MS): m/z calcd for C12H17F3N3 (M+H)+ 260.1374, found 260.1369 
 
2-(4-(2-(Dimethylamino)ethyl)piperazin-1-yl)-5-(trifluoromethyl)aniline S5 
Mp: 107 – 108°C 
1H NMR (300 MHz, CDCl3) δ 2.26 (s, 1H), 2.46 – 2.49 (m, 2H), 2.53 – 2.58 (m, 2H), 2.64 (br 
s, 4H), 2.95 – 2.98 (m, 4H), 4.06 (br s, 2H), 6.92 – 7.03 (m, 3H) 
13C NMR (75 Hz, CDCl3) δ 46.1, 50.6, 54.3, 56.9, 57.1, 111.5 (q, JC-F = 3.8 Hz), 115.5 (q, JC-F 
= 3.8 Hz), 119.7, 124.5 (q, JC-F = 270 Hz), 126.5 (q, JC-F = 33 Hz), 141.64, 142.14 
IR (NaCl, neat): 3458 cm-1 
HRMS (ESI-MS): m/z calcd for C15H24F3N4 (M++H) 317.1953, found 317.1948 
 
2-(4-(Pyridin-2-ylmethyl)piperazin-1-yl)-5-(trifluoromethyl)aniline S6 
Mp 126 – 127°C 
1H NMR (300 MHz, CDCl3) δ 2.67 – 2.69 (m, 4H), 2.97 – 3.00 (m, 4H), 3.74 (s, 2H), 4.07 (br 
s, 2H), 6.92 – 7.04 (m, 3H), 7.16 – 7.20 (m, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.64 – 7.70 (m, 1H), 
8.57 – 8.60 (m, 1H) 
13C NMR (75 MHz, CDCl3) δ 50.7, 54.0, 64.8, 111.6 (q, J = 3.9 Hz), 115.5 (q, J = 4.1 Hz), 
119.7, 122.3, 123.4, 124.6 (q, JC-F = 271.2 Hz), 126.5 (q, JC-F = 32.2 Hz), 136.6, 141.7, 142.2, 
149.5, 158.5 
IR (NaCl, neat): 3187, 3283 cm-1 
HRMS (ESI-MS): m/z calcd for C17H20F3N4 (M++Na) 337.1640, found 337.1594 
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General Procedures for the Synthesis of 2, 3 and SPHINX31 
A solution of trimethylaluminium in toluene (2 M, 3 equiv.) was added dropwise to a solution of aniline S4, S5 
or S6 (1 equiv.) in dichloromethane (0.5 M) at room temperature. The solution was stirred at room temperature 
for 1 hour after which, a solution of methyl 5-(pyridin-4-yl)furan-2-carboxylate5 (1 equiv.) in dichloromethane (1 
M) was added dropwise at room temperature. The reaction solution stirred at room temperature for an 
additional 16 hours. To quench the reaction saturated aqueous Rochelle’s salt solution was added dropwise at 
room temperature and the solution allowed to stir at room temperature for a further 15 minutes. The mixture 
was diluted with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane (× 3). 
The organic extracts were combined and washed with water and brine, then dried (Na2SO4). The solvent was 
removed under reduced pressure and the crude material was purified by flash chromatography on deactivated 
silica gel to afford the product.  
 
2 
Mp: 146-147°C 
1H NMR (300 MHz, CDCl3) δ 2.42 (s, 3H), 2.66-2.76 (m, 4H), 2.99-3.02 (m, 3H), 7.04 
(d, J = 3.6 Hz, 1H), 7.29-7.38 (m, 3H), 7.67-7.69 (m, 1H), 8.70-8.72 (m, 2H), 8.85 (s, 
1H), 9.63 (br s, 1H) 
13C NMR (75 MHz, CDCl3) δ 46.4, 52.2, 56.1, 111.3, 116.5(q, JC-F = 3.8 Hz), 117.7, 
118.5, 121.1, 121.2 (q, JC-F = 3.8 Hz), 124.1 (q, JC-F = 270.1 Hz), 127.8 (q, JC-F = 33.4 
Hz), 133.4, 136.4, 144.3, 148.5, 150.6, 152.9, 155.5 
IR (NaCl, neat): 3306, 1682 cm-1 
HRMS (ESI-MS): m/z calcd for C22H22F3N4O2 (M+H)+ 431.1694, found 431.1689. 
 
3 
Mp: 143 – 144°C 
1H NMR (300 MHz, CDCl3): δ 2.30 (s, 6H), 2.52 – 2.54 (m, 2H), 2.61 – 2.64 (m, 2H), 
2.80 (br s, 4H), 3.02 – 3.05 (m, 4H), 7.05 (d, J = 3.6 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 
7.38 – 7.40 (m, 2H), 7.69 (dd, J = 4.5, 1.5 Hz, 2H), 8.72 (dd, J = 4.5, 1.5 Hz, 2H), 8.86 
(d, J = 1.5 Hz, 1H), 9.65 (br s, 1H) 
13C NMR (75 MHz, CDCl3): δ 45.9, 52.2, 54.7, 56.7, 56.9, 111.3, 116.6 (q, JC-F = 4.5 
Hz), 117.7, 118.5, 121.1, 121.2 (q, JC-F = 4.5 Hz), 124.1 (q, JC-F = 270 Hz), 127.5 (q, JC-
F = 33 Hz), 33.4, 136.4, 144.4, 148.6, 150.7, 152.9, 155.6 
IR (NaCl, neat): 3306, 1673 cm-1 
HRMS (ESI-MS): m/z calcd for C25H29F3N5O2 (M++H) 488.2273, found 488.2268 
 
SPHINX31 
Mp: 157 – 159°C 
1H NMR (300 MHz, CDCl3) δ 2.85 (br s, 4H), 3.04 (br s, 4H), 3.78 (s, 2H), 7.06 (d, J = 
3.7 Hz, 1H), 7.20 (m, 1H), 7.31 – 7.41 (m, 4H), 7.65 – 7.72 (m, 3H), 8.60 (d, J = 4.5 Hz, 
1H), 8.80 – 8.87 (m, 3H), 9.65 (br s, 1H) 
13C NMR (100 MHz, CDCl3) δ 52.2, 54.5, 65.0, 111.3, 116.7 (q, JC-F = 4.5 Hz), 117.7, 
118.5, 121.1, 121.3 (q, JC-F = 4.5 Hz), 122.5, 123.5, 124.1 (q, JC-F = 272 Hz), 128.0 (q, 
JC-F = 34 Hz), 133.5, 136.7, 148.6, 149.7, 150.8, 153.2, 155.7, 157.9 
IR (NaCl, neat): 1669, 3332 cm-1 
HRMS (ESI-MS): m/z calcd for C27H24F3N5O2 (M++H) 508.1960, found 508.1932 
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LCMS traces for Compounds 3 and SPHINX31 
Compound 3 
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SPHINX31 
 
 
 
 
Crystallization, Data collection and Structure determination 
Two different recombinant SRPK1 proteins (aa 42-655,∆256-473,I210T or 58-655,∆256-
473) buffer exchanged into 50 mM HEPES, pH 7.5, 300 mM KCl, 0.5 mM TCEP and 5% 
glycerol were incubated with compound 1 and SPHINX31 at 1 mM concentration, prior to 
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setting up the sitting-drop crystallization at 4 ˚C. For SRPK1-compound 1 complex, the 
crystals were obtained using 20% PEG-6000, 13% Ethylene glycol, 0.1M Tris pH 9.5 and 
0.1M Calcium chloride, while the co-crystals of SRPK1-SPHINX31 complex grew in 22% 
broad-molecular-weight PEG smears and 0.1 M citrate, pH 5.5.6 For SRPK2, the 
recombinant protein was purified using the similar procedure as that used for purification of 
SRPK1. The pure SRPK2 protein in 50 mM HEPES, pH 7.5, 500 mM NaCl and 5% 
glycerol was mixed with 1 mM compound 1, and the complex was crystallized at 4 ˚C 
using the reservoir solution containing 1 M ammonium sulfate and 0.1 M acetate, pH 5.25. 
All crystals were cryo-protected with the mother liquor supplemented with 20% ethylene 
glycol before flash-frozen in liquid nitrogen. Diffraction data collected at Diamond Light 
Source using X-ray at 0.9795 Å wavelength were processed and scaled with XDS7 and 
Scala8 or Aimless9, respectively. Initial structure solutions were obtained with molecular 
replacement method using Phaser and the coordinates of SRPK1 (pdb id: 1WAK)10 or 
SRPK2 (pdb id: 2X7G).  Iterative cycles of model building alternated with structure 
refinement were performed in COOT11 and REFMAC12, respectively. The geometry of the 
final model was verified by MOLPROBITY.13 Data collection and refinement statistics are 
summarized in Supplementary Table 2. 
 
Coordinates and accession codes:  
Coordinates have been deposited with the Protein Data Bank with the designation ‘for 
immediate release upon publication’. The Accession Codes are as follows: 
SRPK1.1 pdb id = 5MXX 
SRPK1.SPHINX31 pdb id = 5MY8 
SRPK2.1 pdb id = 5MYV 
 
2. Biology 
In Vitro Kinase Screening Assay 
Candidate compounds were tested for SRPK1 inhibition using a Kinase-Glo assay 
(Promega, Southampton, UK32). A reaction buffer containing 200 mM Tris pH 7.5, 100 
mM MgCl2 and 0.1 mg/ml BSA was added to 43 µM SRSF1Arg-Ser (RS) peptide (NH2-
RSPSYGRSRSRSRSRSRSRSRSNSRSRSY-OH) and 0.1 µg of purified SRPK1 
(ProQinase, Freiburg, Germany). Candidate compounds were serially diluted from 10 µM 
to 0.001 nM and added to the reaction mixture, wells with omitted SRPK1 kinase and 
omitted compounds were also added as controls. All wells contained 1% DMSO (Fisher 
Scientific, Loughborough, UK). 1 µM ATP was added, wells minus ATP were used as 
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background controls. The plate was then incubated at 30oC for 10 minutes. An equal 
volume of Kinase-Glo (25 µL; Promega) was added to each well and the plate read for 
luminescence using a Fluostar Optima (BMG Labtech). Radioactive kinase assays were 
carried out by the MRC Dundee Kinase Centre. Kinase binding assay was carried out by 
Kinomescan, Discoverex, at 1 µM. Lack of interference with binding to the SRPK1 
substrate was carried out using a dose response curve from 0.5-30 µM. 
 
Protein studies – immunoblotting and immunoprecipitation. 
Whole cell lysate (nuclear and cytoplasmic) protein extracts were prepared as described.14 
The extracts were then immunoblotted using either mouse anti-SRPK1 (anti-SRPK1; BD 
611072; 1:1000), rabbit anti-panVEGF (Santa Cruz A20 sc-152; 1:500), mouse anti-
VEGFxxxb (MAB3045; R&D; 1:500), rabbit anti-VEGF-Ax (a kind gift from Paul Fox, 
Cleveland Clinic Lerner Institute, goat anti-SRSF1 (SC10255; 1:500), mouse anti-SRSF1 
(AK96) (Santa Cruz SC-33562), rabbit anti-SRSF1 (Abcam, Ab-129108 1:2000), goat-anti 
actin (Santa Cruz SC-1615 1:500) or rabbit anti-GAPDH (Sigma G9545, 1:2000). For 
immunoprecipitation phospho-SRSF1 studies, cell lysates were pre-cleared by incubation 
with Protein A Dynabeads (Invitrogen) for 1 h at 4 ºC then incubated with a mix of 1 µg 
mouse anti-SRSF1 (Santa Cruz SC-33562) or IgG control (Mouse IgG2b kappa 
monoclonal (MPC-11) isotype control Ab18457 Abcam) and Protein A Dynabeads 
(Invitrogen). To detect phosphorylated SRSF1, the eluent was immunoblotted with either 
anti-SRSF1 or the anti-Pan-phospho-SR antibody (Millipore MABE50 clone 1H4 1:500). 
 
HERG assay 
Whole cell patch clamp recordings of hERG current (IhERG) were made at 37
oC from 
human embryonic kidney cells (HEK 293) cells stably expressing hERG (generously 
donated by Dr Craig January).15  Cells were maintained in culture and prepared for 
electrophysiological recording as described previously.16,17  Cells were superfused with a 
normal Tyrode’s solution containing (in mM)  140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 
Glucose and 5 HEPES (titrated to pH 7.45 with NaOH). Patch-pipettes were filled with a 
K+-based dialysate containing (in mM): 130 KCl, 1 MgCl2, 5 EGTA, 5 MgATP and 10 
HEPES (titrated to pH 7.2 with KOH). Pipette resistance typically ranged from 1.5–3.5 MΩ 
and ∼70-80% series resistance could be compensated.  Data were acquired using an 
Axopatch 1D amplifier and a CV-4 1/100 headstage and digitised using a Digidata 1200B 
interface (Axon Instruments, USA). Voltage commands were generated and data acquired 
using Clampex 8 (Axon Instruments, USA) and data were stored on the hard-disk of a 
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Viglen computer for off-line analysis. Data were digitized at 10kHz with an appropriate 
bandwidth set on the amplifier.  Compounds were applied using a home-built rapid solution 
exchange device capable of changing superfusate in <1 second. Large scale screening 
was undertaken by Essen Biosciences. 
 
Tm-Shift assay 
Thermal melting experiments were carried out using a Stratagene Mx3005p Real Time 
PCR machine (Agilent Technologies). Proteins at 2 µM concentration buffered in 10 mM 
HEPES, pH 7.5, 500 mM NaCl Were mixed with compounds at a final concentration of 
12.5 µM (final DMSO concentration was 0.02%). Experiments were performed in triplicate 
and data were analysed as previously described.18 
 
Isothermal Titration Calorimetry (ITC) 
The ITC experiment was performed at 30 ˚C using Nano-ITC (TA instrument). The protein 
in 50mM HEPES, pH 7.5, 500mM NaCl, 0.5mM TCEP, 5% glycerol at 50 µM was titrated 
into 6 µM SPHINX31. The heated of binding were analyzed, and the data were fitted to an 
independent binding model using NanoAnalyze program (TA instrument), from which the 
thermodynamic parameters were calculated (∆G = ∆H - T∆S = -RTlnKB, where ∆G, ∆H 
and ∆S are the changes in free energy, enthalpy and entropy of binding, respectively). 
Thermodynamic parameters and binding constants are given in Supplemental Table 2. 
 
Primary human retinal epithelial cell culture 
Primary human RPE isolations were performed on human donor globes obtained within 24 
hours post-mortem from the Bristol Eye bank (Bristol Eye Hospital (BEH)). Retinas with 
choroid-RPE sheets were removed to a petri dish, finely chopped and digested in 
Dulbecco’s Modified Eagle Medium (DMEM):F12(1:1)+GlutaMax (Gibco) supplemented 
with 0.3mg/ml collagenase for 15 minutes at 37°C. Digested choroid-RPE sheets were 
suspended in media (DMEM:F12+GlutaMax) supplemented with 10% fetal bovine serum 
(FBS), 0.5% PenStrep (Invitrogen) and spun at 1500 rpm (251g) for 10 minutes to pellet 
cells. Pellets were resuspended in media supplemented with 25% FBS (Gibco), grown in 
cell culture flasks (Greiner) and split at 80% confluence.  
 
Pharmacological inhibitor treatments. 
Cells at ~70% confluence were serum starved for 24 h and treated with inhibitors at 
concentration noted. To determine pSRSF1 levels, cells were pre-treated with SPHINX31 
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for 1 hr then treated with TNF α (50 ng/ml) for 30 mins. For VEGF immunoblots in PC-3 
cells, cells were treated with inhibitors for 24 h, washed off and lysed 24 h after washing. 
 
Enzyme-linked immunosorbent assay (ELISA). 
10 µg/ml VEGF165b capture antibody (Duoset VEGF ELISA DY-3045; R&D systems) or 
0.25 µg/ml VEGF165a was incubated overnight at room temperature. The plates were 
blocked (1% BSA in PBS) and serial dilutions of recombinant human (rh)VEGF165 or 
rhVEGF165b standards (ranging from 500 pg/ml to 1.95 pg/ml) were added, incubated 
alongside sample lysates, typically 200 µg in 100 µl per well in NP40 lysis buffer. The plate 
was incubated for 2 h at room temperature with shaking, washed and incubated with 100 
µl/well of biotinylated goat anti-human VEGF (0.1 µg/ml; R & D systems) for 2 further 
hours at room temperature. After washing, 100 µl/well of Horseradish Peroxidase (HRP)-
conjugated streptavidin (1:200; R&D Systems) was added and plates were left at room 
temperature for 20 minutes.  
The plates were washed and colour change induced with substrate A and B (DY-999; R&D 
Systems) for 1 hour under light protection. The reaction was stopped by addition of 100 
µl/well of 1M HCl and the absorbance was read immediately in an ELISA plate reader 
(Dynex Technologies Opsys MR system plate reader) at 450 nm with a control reading at 
620 nm. A standard curve was calculated from mean absorbance values of standards 
enabling the estimation of VEGF concentration for each sample.  
 
Laser lesion induction protocol 
Six to eight week-old female C57/B6 mice (Charles River) were anaesthetized with an 
intraperitoneal injection of a mixture of 50mg/kg ketamine and 0.5mg/kg medetomidine. 
The pupils were dilated with 5% phenylephrine hydrochloride and 1% tropicamide. Four 
photocoagulation lesions were delivered with a Micron IV laser photocoagulation 
instrument (Phoenix Instruments) (450mW, 130ms, 75 µm) between the retinal vessels in 
a peripapillary distribution at a distance of 1-2 disc-diameters from the optic nerve in each 
eye. Only laser lesions with a sub-retinal bubble at the time of treatment were included in 
the study. Immediately following laser photocoagulation the animals received topical eye 
drops twice daily (10 µl) as previously described.14 On day 7 and 14 animals were 
anaesthetized and pupils dilated as above, and received 100 µl of 10 mg/ml sodium 
fluorescein in PBS i.p. and retinae imaged using the Micron IV. Animals were culled on 
either day 7 (protein extraction) or day 14 (FFA) and eyes were either unfixed for retinal 
dissection and protein extraction, or fixed and enucleated and choroids stained and 
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examined. Choroidal lesions were imaged and areas traced by a masked observer, lesions 
area was quantified using Image J. 
 
Mass Spectrometry 
Compounds were serially diluted in water (initial stock dissolved in DMSO) from 5 µg/ml to 
0 µg/ml, spiked with an internal standard 1 µg/ml compound 3 to account for any loss of 
samples during preparation and analysed. The chromatograms produced clear peaks at 
the expected molecular weights. The area under the peaks were integrated and plotted 
against concentration to confirm a linear response was observed. After a single topical 
administration mice were killed at time points 1, 4, 8, and 24 hours. Samples, the analyte 
and control treated samples, were homogenized and proteins were precipitated out of the 
samples with an equal volume (300 µl) acetonitrile. An internal standard of 1 µg/ml 
compound 3 was added to samples to account for any loss of samples during preparation. 
The solutions of 50% sample and 50% acetonitrile and 1 µg/ml 3 were centrifuged for 15 
minutes at 4°C to pellet the proteins and the supernatant taken for analysis. Solutions 
were evaporated at 37°C for eight hours and resuspended in 100 µl acetonitrile ready for 
analysis by LCMS using a Varian Triple Quad system. Detection was achieved by positive 
ion electrospray (ESI+) mass spectrometry using a Varain Triple Quad spectrometer in 
multiple ion monitoring (MRM) mode. For SPHINX31 Q1 = 508, Q2 =172. For 3 Q1 = 488 
and Q3 = 443. Mass spectrometer settings were as follows: column temperature 60 ºC; 
capillary voltage: 5 kV; Spray Shield 525 V; Gas Temp: 400 ºC, Nebuliser psi: 60; Analyser 
Temp 42 ºC. Chromatography (flow rate 0.8 mlmin-1) was achieved using a Phenomenex 
Kinetex column (EVO C18 5 µM, 2.1 x 50) equipped with a Phenomenex Security Guard 
precolumn (Security Guard Ultra UHPLC EVO C18). Solvents were: A, HPLC grade H2O 
containing 20% CH3CN + 45 mM ammonium formate pH 8.5; B, HPLC grade CH3CN 
containing 45 mM ammonium formate pH 8.5.  Gradient elution was performed as follows: 
0 min, 90 % A, 5 min, 30 % A, 5.01 min, 100% B; 6 min, 100% B; 6.06 min, 90% A, 15 
min 90% A.  SPHINX31 eluted at 3 min and 3 at 1.9 min. Peaks occurring at these times in 
the SIM chromatograms for each compound were integrated using Varian Integration 
software and used to quantify SPHINX31. 
For quantification of SPHINX31 in mouse plasma stability, metabolite and liver microsome 
stability assays, mass spectrometry was performed at O2H, India, using an Agilent 6410 
series Triple Quad LC-MS with a Waters X Bridge C18 HPLC column (4.6 x 50 mm, 5 µM). 
Detection was achieved by positive ion electrospray (ESI+) mass spectrometry using a 
Agilent 6410 series Triple Quad LC-MS spectrometer in multiple ion monitoring (MRM). 
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For SPHINX31 Q1 = 508.6, Q2 = 420-520. Mass spectrometer settings were as follows: 
column temperature 24 ºC; capillary voltage: 4 kV; Gas Temp: 350 ºC, Gas flow 13 l/min 
Nebuliser psi: 50. Solvents were: A, HPLC grade H2O containing 0.1% Formic acid; B, 
HPLC grade 100% Acetonitrile.  Gradient elution was performed as follows: 0 min, 90% A, 
6 min, 5 % A, 8.5 min, 5% A; 8.6 min, 10% B; 10 min, 10% B. SPHINX31 eluted at 3.9 min. 
 
Electroretinography  
ERG recordings were taken according to ISCEV guidelines using the Phoenix Ganzfeld 
ERG system. 8 week old female C57/Bl6 mice were treated with a single topical 
application of 0.2 µg compound 12, 24 h before ERG recordings and dark adapted for at 
least 12 h and maintained in complete darkness before ERG. Mice were anaesthetized 
with an intraperitoneal injection of a mixture of 50 mg/kg ketamine and 0.5 mg/kg 
medetomidine. The pupils were dilated with 5% phenylephrine hydrochloride and 1% 
tropicamide and kept hydrated with viscotears. Reference electrodes were placed by the 
tail and scalp and the eye was positioned in contact with the Ganzfeld corneal contact 
electrode using Labscribe2 ERG and Ueye Cockpit software. Scotopic ERG recordings 
were taken at 0, 0.02, 0.12, 3.76, 30, 120 and 1920 cd.m.s-2 and photopic recordings at 
120 and 1920 cd.m.s-2 alternating in order between right and left eyes to control for any 
differences. 
 
Statistical Analyses 
If not indicated otherwise, data are shown as mean ± SEM. All data, graphs and statistical 
analyses were calculated with Microsoft Excel (Microsoft Office Software), GraphPad 
Prism (GraphPad Software Inc.) and Image J. All results were considered statistically 
significant at p<0.05 (*), p<0.01 (**) and p<0.001 (***).  
 
 
Constructs and protein expression and purification 
cDNAs encoding several human splicing kinases [SRPK1-2, MSSK1; CLK1-4; DYRK1A-2, 
PRPF4B; PIM1-2] were obtained from synthetic sources and used as templates to amplify 
kinase domain-containing sequences and further sub-cloned into different expression 
vectors, using ligation independent cloning.19   
 
Expression in Escherichia coli  
SRPK1 (aa 42-655), SRPK2 (aa 62-699), CLK2 (aa 135-496), CLK3 (aa 134-484), 
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DYRK1A (aa 127-485), DYRK2 (aa 73-479), MSSK1 (aa 43-533) and PIM2 (aa 1-311) 
were cloned into pNIC28-Bsa4 [pET expression vector with His6 tag in a 22 aa-N-terminal 
fusion peptide, with TEV protease cleavage site, (Kan+)] and co-expressed with λ-
phosphatase in Escherichia coli BL21 (DE3)-R3 cells. CLK1 (aa 148-484) and PIM1 (aa 1-
312) were cloned into PLIC-SGC1 [pET expression vector with His6 tag in a 23 aa-N-
terminal fusion peptide, with TEV protease cleavage site, (Amp+)] and co-expressed with 
λ-phosphatase in Escherichia coli BL21 (DE3)-R3 cells. Transformed cells were initially 
cultured (from an overnight pre-culture) in either terrific broth (TB) medium (supplemented 
with 50 µg/mL of appropriate antibiotic) to OD600 of ∼1.6 at 37 °C, followed by additional 
growth while cooling to 18 °C to an OD600 of ∼3 before induction with 0.5 mM IPTG 
overnight, or cultured in Luria-Bertami (LB) medium to OD600 of ∼0.4 at 37 °C, followed 
by additional growth while cooling to 18 °C to an OD600 of ∼0.7 before induction with 0.5 
mM IPTG overnight. Cells were harvested by centrifugation (JLA 8,100 rotor Beckman 
Coulter, Avanti J-20 XP centrifuge) and were frozen at -20 ⁰C.  Cells expressing His6-
tagged proteins were re-suspended in lysis buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 
10 mM Imidazole, 5% glycerol and 0.5 mM TCEP (Tris(2-carboxyethyl)phosphine 
hydrochloride) in the presence of protease inhibitors cocktail (1 µl/ml) and lysed by 
sonication using a 750 W Sonics Vibra-Cell sonicator, with amplitude set to 35 %, with 
bursts of 5 sec on-10 sec off, for 5 minutes, on ice. PEI (polyethyleneimine) was added to 
a final concentration of 0.15 % and lysates were transferred to centrifuge tubes and 
centrifuged at 53,000×g using a JA-25.50 rotor, for at least 45 minutes, at 4°C. After 
centrifugation, the clarified supernatant was passed through a gravity column of 5 ml Ni-
Sepharose resin, IMAC (GE Healthcare), previously equilibrated in lysis buffer. The resin 
was first washed with 50 ml of lysis buffer containing 1 M NaCl and 30 mM imidazole, then 
with 25 ml of Lysis Buffer containing 100 mM imidazole and finally the protein was eluted 
with 25 ml of Lysis Buffer containing 300 mM imidazole [in the case of CLK1-3, 50 mM L-
Arg/L-Glu was added to all buffers thereafter]. The eluted proteins were collected and 
treated overnight with TEV (Tobacco Etch Virus) protease at 40C to remove the N-terminal 
tag. Digested proteins were loaded onto a nickel column again to remove the cleaved 
hexa-histidine expression tag protease used. The flow-through containing the cleaved 
proteins was collected and concentrated to a 5 ml volume using concentrators (Amicon) 
and injected onto a Superdex 75 or 200 (16/60) gel filtration column on an AKTA system 
(GE Healthcare) pre-equilibrated into GF Buffer (50 mM HEPES pH7.5, 300 mM NaCl, 5% 
glycerol, and 0.5 mM TCEP). The resulting pure protein was stored at −80 °C in 50 mM 
HEPES, pH 7.5, 300 mM NaCl, 0.5 mM TCEP and 5% glycerol.  
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Expression in Spodoptera frugiperda (Sf9) 
CLK4 (aa 126-476) and PRPF4B (aa 665-1004) were cloned into PFB-LIC-Bse 
[Baculovirus transfer vector with His6 tag in a 22 aa-N-terminal fusion peptide, with TEV 
protease cleavage site, (Amp+)] and constructs’ DNA was transformed into the DH10Bac 
Escherichia coli strain (Invitrogen). After transposition the recombinant bacmid DNA was 
then purified and used directly to transfect insect cells (Sf9), using the baculovirus 
expression vector system. Recombinant baculoviruses were produced following an 
established protocol20 based on the Bac-to-Bac ® system (Invitrogen). Sf9 cells were 
routinely grown as a suspension in Sf-900™ II SFM (1×) (Invitrogen) at 27°C, with shaking 
set at 100 rpm. For large scale expression, cells were infected at a density of 2×106/ml 
with recombinant baculovirus (5 ml of virus stock/1L of cultured cells). Seventy-two hours 
after infection, the cultures were collected and centrifuged at 900×g for 20 minutes, 4°C, 
using a JLA 8.1000 rotor on an Avanti J-20XP. The cell pellets were resuspended in cold 
lysis buffer (25ml/pellet from 1L of culture) consisting of 50 mM HEPES [pH 7.5], 500 mM 
NaCl, 5 mM imidazole, 5% glycerol, 0.5 mM TCEP tris(2-carboxyethyl)phosphine) and a 
protease inhibitor cocktail III (1:1000 dilution, Calbiochem). Cell suspensions were lysed 
and proteins were purified following the same methods described above. The correct mass 
and purity for all protein constructs was confirmed by an Agilent 1100 Series LC/MSD TOF 
(Agilent Technologies Inc. – Palo Alto, CA).  
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Supplementary Table 1. Tm data characterizing compound 1 
Kinase ∆Tm (°C) Protein Family 
ACVR1A -0.245 TKL 
ACVR2A -0.34 TKL 
ADRBK2A -0.27 AGC 
AKT3A 0.37 AGC 
BMXA 0.01 Kinase-TK 
CAMKK2B 0.4 Other 
CDC123A 0.19 AGC 
CDK2A 0.06 CMGC 
CDK8A -0.21 CMGC 
CDKL1A -0.31 CMGC 
CHEK2A 0.43 CAMK 
CLK1A 0.67 CMGC 
CLK2A 1.41 CMGC 
CLK3A -0.46 CMGC 
CSNK1G1A -0.055 Other 
CSNK1G3A 0.36 Other 
CSNK2A1A -0.1 Other 
CSNK2A2A 0.62 Other 
FESA -0.06 TK 
GPRK5A -0.28 AGC 
GRK1A 0.01 AGC 
GSG2A 0.1 Other 
GUCY2DA 0.39 Other 
LOC340156A 0.26 CAMK 
MAP2K2A 0.15 STE 
MAPK13A 0.15 CMGC 
MAPK3A -0.6 CMGC 
MAPK8B 0.33 CMGC 
MAPK9A 0.32 CMGC 
MSSK1A 8.49 CMGC 
MST4A 0.1 STE 
MYLK2A 0.7 CAMK 
OSR1A -0.11 STE 
PAK4B 0.68 STE 
PCTK1A 0.23 CMGC 
PIM1A 0.59 CAMK 
PIM1Z 1.235 CAMK 
PIM3A 2.46 CAMK 
PLK4A 0.76 Other 
PRKCL1A -0.4 AGC 
PRKD2A -0.09 AGC 
RPS6KA1A -0.1 AGC 
RPS6KA6A -0.22 AGC 
SLKA 0.34 STE 
SRPK1A 8.54 CMGC 
SRPK2A 4 CMGC 
STK10A 0.35 STE 
STK16A 0.87 Other 
STK17AA -0.23 CAMK 
STK17BA 0.53 CAMK 
STK24A -0.1 STE 
STK33A 0.66 CAMK 
STK38LA 0.56 AGC 
TNIKA 0.13 STE 
YANK1A -0.39 AGC 
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Supplemental Table 2: Crystallographic data and refinement 
 SRPK1-1 SRPK1-SPHINX31 SRPK2-1 
Data collection    
Space group P 43 21 2 P 6522 C 2221 
Cell dimensions    
    a, b, c (Å) 82.6 82.6 133.8 74.9, 74.9, 310.1 188.8, 249.0, 146.7 
    α, β, γ (°)  90.0, 90.0, 90.0 90.0, 90.0, 120.0 90.0, 90.0, 90.0 
Resolution (Å) 29.19-1.75 (1.75-1.78) 28.74-1.70 (1.70-1.79) 29.87-2.90 (3.06-2.90) 
Rmerge 0.059 (0.826) 0.078 (0.799) 0.138 (0.957) 
I /σI 28.4 (3.7) 14.2 (2.7) 9.5 (1.6) 
Completeness (%) 99.8 (96.0) 99.2 (99.0) 99.3 (99.8) 
Redundancy 14.2 (13.8) 7.6 (7.9) 5.8 (6.1) 
    
Refinement    
Resolution (Å) 29.19-1.75 28.74-1.70 29.87-2.90 
No. reflections 47,639 (2,468) 57,614 (8,123) 75,969 (11,061) 
Rwork / Rfree 0.173/ 0.205 0.164/ 0.200 0.199/ 0.217 
No. atoms    
    Protein 2,937 2,971 11,373 
    ligand 26 37 104 
    Water and solvents 276 503 303 
B factors (Å2)    
    Protein 29 30 78 
    ligand 26 27 88 
    Water and solvents 38 45 101 
r.m.s. deviations    
    Bond lengths (Å) 0.013 0.016 0.011 
    Bond angles (°) 1.5 1.6 1.2 
 
Values in brackets are for highest resolution shells 
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Supplemental Figure 1. Comparison of the co-crystal structures of 
SPHINX31.SRPK1 with 1.SRPK2.  
The main interacting residues are labelled. SPHINX31 carbon atoms are coloured in 
yellow and 1 in grey. The main differences between the two ATP sites is due to residue 
changes in the insertion domain helix, in particular the exchange of L231 in SPRK1 with 
M243 (shown as a CPK model and labelled in bold) in SRPK2. The bulkier methionine 
results in re-orientation of the inhibitor and less favourable contacts. The main interacting 
residues are shown in ball and stick representation and are labelled (SRPK1). For all 
SRPK1 residues shown, an essentially similar side chain orientation was observed in 
SRPK2. The SRPK2 residues are therefore not shown or labelled for clarity. Main 
structural elements are labelled as well.  
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Supplemental Figure 2: SPHINX31 is an ATP competitive inhibitor.  
Kinase activity of SRPK1 in the presence of 10 nM compound SPHINX31 and increasing 
concentration of ATP.  
 
 
Supplemental Figure 3: Detection of VEGF-A165b and VEGF-Ax. VEGF-A165b but not 
VEGF-Ax was detected in untreated RPE cells. 
 
 
Supplemental Figure 4. SRPK inhibitors as a class are not toxic. RPE cells were 
treated with cisplatin, pazopanib, or different SRPK1 inhibitors and cytotoxicity measured 
using an MTT assay.  
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Supplemental Figure 5. Dosing with SPHINX31 does not inhibit retinal function. Mice 
(N=3) were dosed six times a day for 14 days, and retinal function measured by 
electroretinography. No changes were seen compared with vehicle control treatment. 
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Supplemental Figure 6. SPHINX31 inhibits hERG with an IC50 of 300 nM. hERG 
activity (tail current, a. of compounds S2 and SPHINX31 were measured. b. Fractional 
block was determined (example for compound S2 shown). Compound S2 had an IC50 of 
36 nM. c. SPHINX31 had an IC50 of 300 nM. 
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Supplemental Figure 7. VEGF-A165b, but not VEGF-Ax, was expressed in mouse 
retina after treatment with SPHINX31. Six C57/Bl6 mice were subjected to laser CNV 
and killed after 4 days. Three retinae were pooled and protein extracted and subjected to a. 
immunoblotting for VEGF-A165b and VEGF-Ax. No VEGF-Ax was seen in mouse retina or 
human RPE cells, but was seen in mouse colon spleen and kidney. b-c. Densitometric 
quantification of western blots. ELISA for d. VEGF-A165a and e. VEGF-A165b demonstrated 
that f. a switch in isoform expression had occurred.  
 
